-
公开(公告)号:US20230391850A1
公开(公告)日:2023-12-07
申请号:US18249525
申请日:2021-11-10
Applicant: Cytiva BioProcess R&D AB
Inventor: Mats Ander , Gustav Rodrigo , Tomas Björkman
CPC classification number: C07K16/065 , B01D15/3809 , B01J20/286 , B01J20/3212 , B01J20/3274 , B01J20/28038 , C07K14/31
Abstract: The invention relates to an alkali-stable mutated Fc-binding Protein A domain, having at least 95% identity to SEQ ID NO: 8 or SEQ ED NO: 9.
-
公开(公告)号:US11807666B2
公开(公告)日:2023-11-07
申请号:US18059929
申请日:2022-11-29
Applicant: Cytiva BioProcess R&D AB
Inventor: Martin Hall , Karolina Busson , Jean-Luc Maloisel , Helena Skoglar
IPC: C07K1/18 , B01J41/20 , B01D15/36 , B01D15/38 , A61K38/36 , A61K38/48 , A61K35/16 , C12N9/64 , B01D15/34 , C07K14/47 , C07K14/755 , C07K14/765 , C07K16/00 , A61K38/00
CPC classification number: C07K1/18 , A61K35/16 , A61K38/36 , A61K38/4846 , B01D15/34 , B01D15/363 , B01D15/3847 , B01J41/20 , C07K14/472 , C07K14/755 , C07K14/765 , C07K16/00 , C12N9/644 , C12N9/6424 , C12Y304/21022 , A61K38/00
Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of proteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
-
公开(公告)号:US11685764B2
公开(公告)日:2023-06-27
申请号:US17221438
申请日:2021-04-02
Applicant: Cytiva BioProcess R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: A23J1/00 , C07K1/22 , B01D15/38 , B01J20/24 , B01J20/28 , B01J20/286 , B01J20/32 , C07K14/31 , C07K16/00 , C07K16/06 , C07K17/10
CPC classification number: C07K1/22 , B01D15/3809 , B01J20/24 , B01J20/286 , B01J20/28016 , B01J20/28078 , B01J20/3212 , B01J20/3274 , C07K14/31 , C07K16/00 , C07K16/065 , C07K17/10
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:
a) the ligands comprise multimers of alkali-stabilized Protein A domains, and
b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50, v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.-
公开(公告)号:US11680081B2
公开(公告)日:2023-06-20
申请号:US16955119
申请日:2018-12-13
Applicant: Cytiva Bioprocess R&D AB
Inventor: Gustav Rodrigo , Mats Ander , Ronnie Palmgren , Tomas Bjorkman
CPC classification number: C07K1/22 , B01D15/3809 , B01J20/24 , B01J20/288 , B01J20/28016 , B01J20/3071 , B01J20/3212 , B01J20/3217 , B01J20/3274 , B01J20/3295 , C07K16/00 , B01J2220/54
Abstract: Methods that include providing and reacting a solid support and an alkali-stable ligand derived from an immunoglobulin-binding bacterial protein to form a separation matrix having covalently coupled alkali-stable ligands; and washing with a wash solution comprising at least 10 mM of an alkali metal hydroxide.
-
公开(公告)号:US11623941B2
公开(公告)日:2023-04-11
申请号:US16884475
申请日:2020-05-27
Applicant: Cytiva BioProcess R&D AB
Inventor: Annika Kristina Forss , Gustav Jose Rodrigo , Tomas Bjorkman , Jesper Ulf Hansson , Mats Ander
IPC: C07K1/22 , B01D15/08 , C07K16/12 , C07K17/10 , B01J20/286 , C07K14/31 , C07K16/06 , B01D15/00 , B01J20/32
Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, b) contacting a liquid sample comprising an immunoglobulin with the separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein the alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 51 or SEQ ID NO: 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO: 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO: 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号:US20220362744A1
公开(公告)日:2022-11-17
申请号:US17853514
申请日:2022-06-29
Applicant: Cytiva BioProcess R&D AB
Inventor: Ronnie Palmgren , Jean-Luc Maloisel , Gustav Rodrigo , Tomas Bjorkman
Abstract: A separation matrix comprising porous particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 5 mg/ml, the volume-weighted median diameter of said porous particles is at least 10 and below 30 μm and the said porous particles have a gel phase distribution coefficient, expressed as KD for dextran of molecular weight 110 kDa, of 0.5-0.9.
-
公开(公告)号:US20220219141A1
公开(公告)日:2022-07-14
申请号:US17605502
申请日:2020-04-28
Applicant: Cytiva Bioprocess R&D AB
Inventor: Susanna Lindberg , Jonas Gustafsson , Linn Carlsson , Anders Hagvall , Erik Ringberg , David Jansson
IPC: B01J20/291 , B01J20/24 , B01J20/28 , B01J20/30
Abstract: The invention discloses method for manufacturing agar or agarose beads, comprising the steps of: a) providing a water phase comprising an aqueous solution of agar or agarose at a temperature of 40-100° C.: b) providing an oil phase comprising a water-immiscible solvent and an emulsifier at a temperature of 40-100° C.; c) emulsifying the water phase in the oil phase to form a water-in-oil emulsion: d) cooling the water-in-oil emulsion to a temperature below a gelation temperature of the agar or agarose to form a dispersion of solidified agar or agarose beads: and c) recovering agar or agarose beads from dispersion, wherein the emulsifier comprises a phosphate ester of an alkoxy lated fatty alcohol.
-
公开(公告)号:US11236216B2
公开(公告)日:2022-02-01
申请号:US15578074
申请日:2016-05-27
Applicant: Cytiva BioProcess R&D AB
Inventor: Per Erik Emilsson , Susanna Klara Margareta Lindberg , Jonny Wernersson , Jonas Gustafsson , Adam Hurynowicz
Abstract: The invention discloses a method of manufacturing polysaccharide beads, comprising the steps of: i) providing a water phase comprising an aqueous solution of a polysaccharide; ii) providing an oil phase comprising at least one water-immiscible organic solvent and at least one oil-soluble emulsifier; iii) emulsifying the water phase in the oil phase to form a water-in-oil (w/o) emulsion; and iv) inducing solidification of the water phase in the w/o emulsion, wherein the organic solvent is an aliphatic or alicyclic ketone or ether.
-
79.
公开(公告)号:US20210291143A1
公开(公告)日:2021-09-23
申请号:US17107600
申请日:2020-11-30
Applicant: Cytiva Bioprocess R&D AB
Inventor: Martin HALL , Sture LARSSON , Andreas MURANYI , Gustav RODRIGO , Jinyu ZOU , Per-Mikael ABERG
IPC: B01J20/24 , B01D15/38 , B01J20/286 , C07K1/22 , B01J20/32 , C07K14/31 , C07K16/00 , C07K17/00 , B01J20/28 , B01J20/285 , B01J20/289 , C07K17/10
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
-
公开(公告)号:US20210221841A1
公开(公告)日:2021-07-22
申请号:US17221438
申请日:2021-04-02
Applicant: Cytiva BioProcess R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , B01D15/38 , B01J20/24 , B01J20/28 , B01J20/286 , B01J20/32 , C07K14/31 , C07K16/00 , C07K16/06 , C07K17/10
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
-
-
-
-
-
-
-
-